img

Global Monoclonal Antibody Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Monoclonal Antibody Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to bind monospecifically to certain cells or proteins.
Due to the COVID-19 pandemic, the global Monoclonal Antibody Treatment market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Cancer accounting for % of the Monoclonal Antibody Treatment global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The global key companies of Monoclonal Antibody Treatment include Pfizer, Bayer, Sanofi, Merck, GlaxoSmithKline, Roche, Novartis, AbbVie and Shanghai Junshi Biosciences Co.,Ltd, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Monoclonal Antibody Treatment market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Monoclonal Antibody Treatment landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Monoclonal Antibody Treatment market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Monoclonal Antibody Treatment market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Monoclonal Antibody Treatment market. Readers of the report can become informed about current and future trends of the global Monoclonal Antibody Treatment market and how they will impact market growth during the forecast period.



By Company


Pfizer
Bayer
Sanofi
Merck
GlaxoSmithKline
Roche
Novartis
AbbVie
Shanghai Junshi Biosciences Co.,Ltd
Innovent Biologics
Jiangsu Hengrui Medicine Co.,Ltd.
BeiGene, Ltd.
Grand Pharmaceutical (China) Co., Ltd
Henlius
Segment by Type
Cancer
Autoimmune Diseases
Exogenous Infection
Hematological Diseases

Segment by Application


Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Monoclonal Antibody Treatment in global and regional level.
Chapter 3Detailed analysis of Monoclonal Antibody Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Monoclonal Antibody Treatment revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal Antibody Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Cancer
1.2.3 Autoimmune Diseases
1.2.4 Exogenous Infection
1.2.5 Hematological Diseases
1.3 Market by Application
1.3.1 Global Monoclonal Antibody Treatment Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Monoclonal Antibody Treatment Market Size (2018-2034)
2.2 Monoclonal Antibody Treatment Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Monoclonal Antibody Treatment Market Size by Region (2018-2024)
2.4 Global Monoclonal Antibody Treatment Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Monoclonal Antibody Treatment Countries Ranking by Market Size
3 Monoclonal Antibody Treatment Competitive by Company
3.1 Global Monoclonal Antibody Treatment Revenue by Players
3.1.1 Global Monoclonal Antibody Treatment Revenue by Players (2018-2024)
3.1.2 Global Monoclonal Antibody Treatment Market Share by Players (2018-2024)
3.2 Global Monoclonal Antibody Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Monoclonal Antibody Treatment Revenue
3.4 Global Monoclonal Antibody Treatment Market Concentration Ratio
3.4.1 Global Monoclonal Antibody Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal Antibody Treatment Revenue in 2022
3.5 Global Key Players of Monoclonal Antibody Treatment Head office and Area Served
3.6 Global Key Players of Monoclonal Antibody Treatment, Product and Application
3.7 Global Key Players of Monoclonal Antibody Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Monoclonal Antibody Treatment Breakdown Data by Type
4.1 Global Monoclonal Antibody Treatment Historic Revenue by Type (2018-2024)
4.2 Global Monoclonal Antibody Treatment Forecasted Revenue by Type (2024-2034)
5 Global Monoclonal Antibody Treatment Breakdown Data by Application
5.1 Global Monoclonal Antibody Treatment Historic Market Size by Application (2018-2024)
5.2 Global Monoclonal Antibody Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Monoclonal Antibody Treatment Revenue by Company (2021-2024)
6.2 North America Monoclonal Antibody Treatment Revenue by Type (2018-2034)
6.3 North America Monoclonal Antibody Treatment Revenue by Application (2018-2034)
6.4 North America Monoclonal Antibody Treatment Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Monoclonal Antibody Treatment Revenue by Company (2021-2024)
7.2 Europe Monoclonal Antibody Treatment Revenue by Type (2018-2034)
7.3 Europe Monoclonal Antibody Treatment Revenue by Application (2018-2034)
7.4 Europe Monoclonal Antibody Treatment Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Monoclonal Antibody Treatment Revenue by Company (2021-2024)
8.2 Asia Pacific Monoclonal Antibody Treatment Revenue by Type (2018-2034)
8.3 Asia Pacific Monoclonal Antibody Treatment Revenue by Application (2018-2034)
8.4 Asia Pacific Monoclonal Antibody Treatment Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Monoclonal Antibody Treatment Revenue by Company (2021-2024)
9.2 Latin America Monoclonal Antibody Treatment Revenue by Type (2018-2034)
9.3 Latin America Monoclonal Antibody Treatment Revenue by Application (2018-2034)
9.4 Latin America Monoclonal Antibody Treatment Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Monoclonal Antibody Treatment Revenue by Company (2021-2024)
10.2 Middle East and Africa Monoclonal Antibody Treatment Revenue by Type (2018-2034)
10.3 Middle East and Africa Monoclonal Antibody Treatment Revenue by Application (2018-2034)
10.4 Middle East and Africa Monoclonal Antibody Treatment Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Monoclonal Antibody Treatment Products and Services
11.1.4 Pfizer Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.1.5 Pfizer Monoclonal Antibody Treatment SWOT Analysis
11.1.6 Pfizer Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Monoclonal Antibody Treatment Products and Services
11.2.4 Bayer Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.2.5 Bayer Monoclonal Antibody Treatment SWOT Analysis
11.2.6 Bayer Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Monoclonal Antibody Treatment Products and Services
11.3.4 Sanofi Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.3.5 Sanofi Monoclonal Antibody Treatment SWOT Analysis
11.3.6 Sanofi Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Monoclonal Antibody Treatment Products and Services
11.4.4 Merck Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.4.5 Merck Monoclonal Antibody Treatment SWOT Analysis
11.4.6 Merck Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Monoclonal Antibody Treatment Products and Services
11.5.4 GlaxoSmithKline Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.5.5 GlaxoSmithKline Monoclonal Antibody Treatment SWOT Analysis
11.5.6 GlaxoSmithKline Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Monoclonal Antibody Treatment Products and Services
11.6.4 Roche Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.6.5 Roche Monoclonal Antibody Treatment SWOT Analysis
11.6.6 Roche Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Monoclonal Antibody Treatment Products and Services
11.7.4 Novartis Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.7.5 Novartis Monoclonal Antibody Treatment SWOT Analysis
11.7.6 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Monoclonal Antibody Treatment Products and Services
11.8.4 AbbVie Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.8.5 AbbVie Monoclonal Antibody Treatment SWOT Analysis
11.8.6 AbbVie Recent Development
11.9 Shanghai Junshi Biosciences Co.,Ltd
11.9.1 Shanghai Junshi Biosciences Co.,Ltd Company Details
11.9.2 Shanghai Junshi Biosciences Co.,Ltd Business Overview
11.9.3 Shanghai Junshi Biosciences Co.,Ltd Monoclonal Antibody Treatment Products and Services
11.9.4 Shanghai Junshi Biosciences Co.,Ltd Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.9.5 Shanghai Junshi Biosciences Co.,Ltd Monoclonal Antibody Treatment SWOT Analysis
11.9.6 Shanghai Junshi Biosciences Co.,Ltd Recent Development
11.10 Innovent Biologics
11.10.1 Innovent Biologics Company Details
11.10.2 Innovent Biologics Business Overview
11.10.3 Innovent Biologics Monoclonal Antibody Treatment Products and Services
11.10.4 Innovent Biologics Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.10.5 Innovent Biologics Monoclonal Antibody Treatment SWOT Analysis
11.10.6 Innovent Biologics Recent Development
11.11 Jiangsu Hengrui Medicine Co.,Ltd.
11.11.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Details
11.11.2 Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
11.11.3 Jiangsu Hengrui Medicine Co.,Ltd. Monoclonal Antibody Treatment Products and Services
11.11.4 Jiangsu Hengrui Medicine Co.,Ltd. Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.11.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Development
11.12 BeiGene, Ltd.
11.12.1 BeiGene, Ltd. Company Details
11.12.2 BeiGene, Ltd. Business Overview
11.12.3 BeiGene, Ltd. Monoclonal Antibody Treatment Products and Services
11.12.4 BeiGene, Ltd. Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.12.5 BeiGene, Ltd. Recent Development
11.13 Grand Pharmaceutical (China) Co., Ltd
11.13.1 Grand Pharmaceutical (China) Co., Ltd Company Details
11.13.2 Grand Pharmaceutical (China) Co., Ltd Business Overview
11.13.3 Grand Pharmaceutical (China) Co., Ltd Monoclonal Antibody Treatment Products and Services
11.13.4 Grand Pharmaceutical (China) Co., Ltd Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.13.5 Grand Pharmaceutical (China) Co., Ltd Recent Development
11.14 Henlius
11.14.1 Henlius Company Details
11.14.2 Henlius Business Overview
11.14.3 Henlius Monoclonal Antibody Treatment Products and Services
11.14.4 Henlius Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024)
11.14.5 Henlius Recent Development
12 Monoclonal Antibody Treatment Market Dynamics
12.1 Monoclonal Antibody Treatment Industry Trends
12.2 Monoclonal Antibody Treatment Market Drivers
12.3 Monoclonal Antibody Treatment Market Challenges
12.4 Monoclonal Antibody Treatment Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Monoclonal Antibody Treatment Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Cancer
Table 3. Key Players of Autoimmune Diseases
Table 4. Key Players of Exogenous Infection
Table 5. Key Players of Hematological Diseases
Table 6. Global Monoclonal Antibody Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 7. Global Monoclonal Antibody Treatment Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 8. Global Monoclonal Antibody Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Monoclonal Antibody Treatment Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 10. Global Monoclonal Antibody Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 11. Global Monoclonal Antibody Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 12. Global Monoclonal Antibody Treatment Market Share by Players (2018-2024)
Table 13. Global Top Monoclonal Antibody Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody Treatment as of 2022)
Table 14. Ranking of Global Top Monoclonal Antibody Treatment Companies by Revenue (US$ Million) in 2022
Table 15. Global 5 Largest Players Market Share by Monoclonal Antibody Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 16. Global Key Players of Monoclonal Antibody Treatment, Headquarters and Area Served
Table 17. Global Key Players of Monoclonal Antibody Treatment, Product and Application
Table 18. Global Key Players of Monoclonal Antibody Treatment, Date of Enter into This Industry
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Monoclonal Antibody Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 21. Global Monoclonal Antibody Treatment Revenue Market Share by Type (2018-2024)
Table 22. Global Monoclonal Antibody Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 23. Global Monoclonal Antibody Treatment Revenue Market Share by Type (2024-2034)
Table 24. Global Monoclonal Antibody Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 25. Global Monoclonal Antibody Treatment Revenue Market Share by Application (2018-2024)
Table 26. Global Monoclonal Antibody Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 27. Global Monoclonal Antibody Treatment Revenue Market Share by Application (2024-2034)
Table 28. North America Monoclonal Antibody Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 29. North America Monoclonal Antibody Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 30. North America Monoclonal Antibody Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 31. North America Monoclonal Antibody Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 32. North America Monoclonal Antibody Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 33. North America Monoclonal Antibody Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 34. North America Monoclonal Antibody Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 35. North America Monoclonal Antibody Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 36. Europe Monoclonal Antibody Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 37. Europe Monoclonal Antibody Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 38. Europe Monoclonal Antibody Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 39. Europe Monoclonal Antibody Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 40. Europe Monoclonal Antibody Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 41. Europe Monoclonal Antibody Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 42. Europe Monoclonal Antibody Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 43. Europe Monoclonal Antibody Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 44. Asia Pacific Monoclonal Antibody Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 45. Asia Pacific Monoclonal Antibody Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 46. Asia Pacific Monoclonal Antibody Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 47. Asia Pacific Monoclonal Antibody Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 48. Asia Pacific Monoclonal Antibody Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 49. Asia-Pacific Monoclonal Antibody Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 50. Asia Pacific Monoclonal Antibody Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 51. Asia Pacific Monoclonal Antibody Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 52. Latin America Monoclonal Antibody Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 53. Latin America Monoclonal Antibody Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 54. Latin America Monoclonal Antibody Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 55. Latin America Monoclonal Antibody Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 56. Latin America Monoclonal Antibody Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 57. Latin America Monoclonal Antibody Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 58. Latin America Monoclonal Antibody Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 59. Latin America Monoclonal Antibody Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 60. Middle East and Africa Monoclonal Antibody Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 61. Middle East and Africa Monoclonal Antibody Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Monoclonal Antibody Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Monoclonal Antibody Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 64. Middle East and Africa Monoclonal Antibody Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Monoclonal Antibody Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 66. Middle East and Africa Monoclonal Antibody Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Monoclonal Antibody Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 68. Pfizer Company Details
Table 69. Pfizer Business Overview
Table 70. Pfizer Monoclonal Antibody Treatment Product and Services
Table 71. Pfizer Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 72. Pfizer Monoclonal Antibody Treatment SWOT Analysis
Table 73. Pfizer Recent Development
Table 74. Bayer Company Details
Table 75. Bayer Business Overview
Table 76. Bayer Monoclonal Antibody Treatment Product and Services
Table 77. Bayer Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 78. Bayer Monoclonal Antibody Treatment SWOT Analysis
Table 79. Bayer Recent Development
Table 80. Sanofi Company Details
Table 81. Sanofi Business Overview
Table 82. Sanofi Monoclonal Antibody Treatment Product and Services
Table 83. Sanofi Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 84. Sanofi Monoclonal Antibody Treatment SWOT Analysis
Table 85. Sanofi Recent Development
Table 86. Merck Company Details
Table 87. Merck Business Overview
Table 88. Merck Monoclonal Antibody Treatment Product and Services
Table 89. Merck Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 90. Merck Monoclonal Antibody Treatment SWOT Analysis
Table 91. Merck Recent Development
Table 92. GlaxoSmithKline Company Details
Table 93. GlaxoSmithKline Business Overview
Table 94. GlaxoSmithKline Monoclonal Antibody Treatment Product and Services
Table 95. GlaxoSmithKline Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 96. GlaxoSmithKline Monoclonal Antibody Treatment SWOT Analysis
Table 97. GlaxoSmithKline Recent Development
Table 98. Roche Company Details
Table 99. Roche Business Overview
Table 100. Roche Monoclonal Antibody Treatment Product and Services
Table 101. Roche Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 102. Roche Monoclonal Antibody Treatment SWOT Analysis
Table 103. Roche Recent Development
Table 104. Novartis Company Details
Table 105. Novartis Business Overview
Table 106. Novartis Monoclonal Antibody Treatment Product and Services
Table 107. Novartis Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 108. Novartis Monoclonal Antibody Treatment SWOT Analysis
Table 109. Novartis Recent Development
Table 110. AbbVie Company Details
Table 111. AbbVie Business Overview
Table 112. AbbVie Monoclonal Antibody Treatment Product and Services
Table 113. AbbVie Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 114. AbbVie Monoclonal Antibody Treatment SWOT Analysis
Table 115. AbbVie Recent Development
Table 116. Shanghai Junshi Biosciences Co.,Ltd Company Details
Table 117. Shanghai Junshi Biosciences Co.,Ltd Business Overview
Table 118. Shanghai Junshi Biosciences Co.,Ltd Monoclonal Antibody Treatment Product and Services
Table 119. Shanghai Junshi Biosciences Co.,Ltd Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 120. Shanghai Junshi Biosciences Co.,Ltd Monoclonal Antibody Treatment SWOT Analysis
Table 121. Shanghai Junshi Biosciences Co.,Ltd Recent Development
Table 122. Innovent Biologics Company Details
Table 123. Innovent Biologics Business Overview
Table 124. Innovent Biologics Monoclonal Antibody Treatment Product and Services
Table 125. Innovent Biologics Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 126. Innovent Biologics Monoclonal Antibody Treatment SWOT Analysis
Table 127. Innovent Biologics Recent Development
Table 128. Jiangsu Hengrui Medicine Co.,Ltd. Company Details
Table 129. Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
Table 130. Jiangsu Hengrui Medicine Co.,Ltd. Monoclonal Antibody Treatment Product and Services
Table 131. Jiangsu Hengrui Medicine Co.,Ltd. Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 132. Jiangsu Hengrui Medicine Co.,Ltd. Recent Development
Table 133. BeiGene, Ltd. Company Details
Table 134. BeiGene, Ltd. Business Overview
Table 135. BeiGene, Ltd. Monoclonal Antibody Treatment Product and Services
Table 136. BeiGene, Ltd. Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 137. BeiGene, Ltd. Recent Development
Table 138. Grand Pharmaceutical (China) Co., Ltd Company Details
Table 139. Grand Pharmaceutical (China) Co., Ltd Business Overview
Table 140. Grand Pharmaceutical (China) Co., Ltd Monoclonal Antibody Treatment Product and Services
Table 141. Grand Pharmaceutical (China) Co., Ltd Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 142. Grand Pharmaceutical (China) Co., Ltd Recent Development
Table 143. Henlius Company Details
Table 144. Henlius Business Overview
Table 145. Henlius Monoclonal Antibody Treatment Product and Services
Table 146. Henlius Monoclonal Antibody Treatment Revenue in Monoclonal Antibody Treatment Business (2018-2024) & (US$ Million)
Table 147. Henlius Recent Development
Table 148. Monoclonal Antibody Treatment Market Trends
Table 149. Monoclonal Antibody Treatment Market Drivers
Table 150. Monoclonal Antibody Treatment Market Challenges
Table 151. Monoclonal Antibody Treatment Market Restraints
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Monoclonal Antibody Treatment Product Picture
Figure 2. Global Monoclonal Antibody Treatment Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Monoclonal Antibody Treatment Market Share by Type: 2022 VS 2034
Figure 4. Cancer Features
Figure 5. Autoimmune Diseases Features
Figure 6. Exogenous Infection Features
Figure 7. Hematological Diseases Features
Figure 8. Global Monoclonal Antibody Treatment Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 9. Global Monoclonal Antibody Treatment Market Share by Application: 2022 VS 2034
Figure 10. Hospitals
Figure 11. Clinics
Figure 12. Others
Figure 13. Monoclonal Antibody Treatment Report Years Considered
Figure 14. Global Monoclonal Antibody Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Monoclonal Antibody Treatment Market Size 2018-2034 (US$ Million)
Figure 16. Global Monoclonal Antibody Treatment Market Size Market Share by Region: 2022 VS 2034
Figure 17. Global Monoclonal Antibody Treatment Revenue Market Share by Region in 2018 VS 2022
Figure 18. Global Monoclonal Antibody Treatment Revenue Market Share Forecast by Region (2024-2034)
Figure 19. Global Top 10 Monoclonal Antibody Treatment Countries Ranking by Market Size (US$ Million) in 2022
Figure 20. Global Monoclonal Antibody Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 21. Global Monoclonal Antibody Treatment Market Share by Players in 2022
Figure 22. Global Top Monoclonal Antibody Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody Treatment as of 2022)
Figure 23. The Top 10 and 5 Players Market Share by Monoclonal Antibody Treatment Revenue in 2022
Figure 24. North America Monoclonal Antibody Treatment Revenue Market Share by Company in 2022
Figure 25. North America Monoclonal Antibody Treatment Revenue Market Share by Type (2018-2034)
Figure 26. North America Monoclonal Antibody Treatment Revenue Market Share by Application (2018-2034)
Figure 27. North America Monoclonal Antibody Treatment Revenue Share by Country (2018-2034)
Figure 28. United States Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 29. Canada Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 30. Europe Monoclonal Antibody Treatment Revenue Market Share by Company in 2022
Figure 31. Europe Monoclonal Antibody Treatment Revenue Market Share by Type (2018-2034)
Figure 32. Europe Monoclonal Antibody Treatment Revenue Market Share by Application (2018-2034)
Figure 33. Europe Monoclonal Antibody Treatment Revenue Share by Country (2018-2034)
Figure 34. Germany Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 35. France Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 36. U.K. Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 37. Italy Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 38. Russia Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 39. Asia Pacific Monoclonal Antibody Treatment Revenue Market Share by Company in 2022
Figure 40. Asia Pacific Monoclonal Antibody Treatment Revenue Market Share by Type (2018-2034)
Figure 41. Asia Pacific Monoclonal Antibody Treatment Revenue Market Share by Application (2018-2034)
Figure 42. Asia Pacific Monoclonal Antibody Treatment Revenue Share by Region (2018-2034)
Figure 43. China Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 44. Japan Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 45. South Korea Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 46. India Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 47. Australia Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 48. China Taiwan Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 49. Indonesia Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 50. Thailand Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 51. Malaysia Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 52. Latin America Monoclonal Antibody Treatment Revenue Market Share by Company in 2022
Figure 53. Latin America Monoclonal Antibody Treatment Revenue Market Share by Type (2018-2034)
Figure 54. Latin America Monoclonal Antibody Treatment Revenue Market Share by Application (2018-2034)
Figure 55. Latin America Monoclonal Antibody Treatment Revenue Share by Country (2018-2034)
Figure 56. Mexico Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 57. Brazil Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 58. Argentina Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 59. Middle East and Africa Monoclonal Antibody Treatment Revenue Market Share by Company in 2022
Figure 60. Middle East and Africa Monoclonal Antibody Treatment Revenue Market Share by Type (2018-2034)
Figure 61. Middle East and Africa Monoclonal Antibody Treatment Revenue Market Share by Application (2018-2034)
Figure 62. Middle East and Africa Monoclonal Antibody Treatment Revenue Share by Country (2018-2034)
Figure 63. Turkey Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 64. Saudi Arabia Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 65. UAE Monoclonal Antibody Treatment Revenue (2018-2034) & (US$ Million)
Figure 66. Pfizer Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 67. Bayer Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 68. Sanofi Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 69. Merck Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 70. GlaxoSmithKline Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 71. Roche Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 72. Novartis Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 73. AbbVie Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 74. Shanghai Junshi Biosciences Co.,Ltd Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 75. Innovent Biologics Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 76. Jiangsu Hengrui Medicine Co.,Ltd. Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 77. BeiGene, Ltd. Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 78. Grand Pharmaceutical (China) Co., Ltd Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 79. Henlius Revenue Growth Rate in Monoclonal Antibody Treatment Business (2018-2024)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed